Trial Profile

Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MB 102 Mustang Bio (Primary) ; Cyclophosphamide; Fludarabine
Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm
Focus Adverse reactions; First in man; Therapeutic Use

16 Sep 2025 Planned End Date changed from 18 Aug 2025 to 6 Aug 2026.
16 Sep 2025 Planned primary completion date changed from 18 Aug 2025 to 6 Aug 2026.
17 Jun 2025 Planned End Date changed from 15 Dec 2024 to 18 Aug 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com